vTv Therapeutics (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company that discovers, develops and sells orally administered small molecule drug candidates worldwide. The company’s drug candidate for the treatment of Alzheimer’s disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end-products, which is in Phase III clinical trials. Its Type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in phase II clinical trials. For more information, visit the company’s website at www.vtvtherapeutics.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com